ArticleFrontiers in pharmacology2021

Resibufogenin Suppresses Triple-Negative Breast Cancer Angiogenesis by Blocking VEGFR2-Mediated Signaling Pathway.

Ting Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.